Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
Albiglutide in the Harmony Outcomes trial showed a 22% reduction in MACE in patients with established ASCVD (20), while exenatide (EXSCEL trial) (21) and lixisenatide (ELIXA trial) (22) did not meet superiority, though both demonstrated CV safety
This can make them appealing to people taking GLP-1 medications who may feel full quickly or struggle with appetite
That's the real victory
But Trulicity may cause pancreatitis
Eli Lilly ran the SURPASS trials to support a diabetes indication and the SURMOUNT trials to support an obesity indication
US$ 22.67
US$ 27.07
US$ 22.35
